The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more
Equillium, a biotech developing therapies for graft-versus-host-disease and severe asthma, raised $65 million by offering 4.7 million shares at $14, the low end of the $14 to $16 range. At pricing, the La Jolla, CA-based company will command a market value of...read more
ThiS 5-IPO week is led by cloud-based business planning software provider Anaplan, which hopes to follow in the footsteps of the many other high-flying SaaS IPOs of 2018 (31% average return). Also pricing this week is Livent, which produces lithium...read more
Equillium, a Phase 1 biotech developing monoclonal antibody therapies for aGVHD & cGVHD, announced terms for its IPO on Tuesday. The La Jolla, CA-based company plans to raise $70 million by offering 4.7 million shares at a price range of $14 to $16. At...read more
US IPO Weekly Recap: Despite sell-off, 4 IPOs price with unicorn Anaplan up 43%
The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more
Equillium prices IPO at $14, the low end of the range
Equillium, a biotech developing therapies for graft-versus-host-disease and severe asthma, raised $65 million by offering 4.7 million shares at $14, the low end of the $14 to $16 range. At pricing, the La Jolla, CA-based company will command a market value of...read more
US IPO Week Ahead: Anaplan leads this upcoming 5-IPO week
ThiS 5-IPO week is led by cloud-based business planning software provider Anaplan, which hopes to follow in the footsteps of the many other high-flying SaaS IPOs of 2018 (31% average return). Also pricing this week is Livent, which produces lithium...read more
Immuno-inflammatory biotech Equillium sets terms for $70 million IPO
Equillium, a Phase 1 biotech developing monoclonal antibody therapies for aGVHD & cGVHD, announced terms for its IPO on Tuesday. The La Jolla, CA-based company plans to raise $70 million by offering 4.7 million shares at a price range of $14 to $16. At...read more